Phase I/II study of Carfilzomib in combination with bendamustine and dexamethasone in patients with newly diagnosed multiple myeloma

Protocol: 
AAAJ2359
Phase: 
I/II

Phase I/II study of Carfilzomib in combination with bendamustine and dexamethasone in patients with newly diagnosed multiple myeloma

The goal of this clinical research study is to find the highest tolerable dose of carfilzomib with the combination of bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma. The response rate and the safety of this drug combination will also be studied.

Are you Eligible? (Inclusion Criteria)

Patients must have histologically or cytologically confirmed symptomatic MM, Salmon-Durie Stage II or III, or International Staging System II or III. Patients must be untreated.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States